A Drosophila Model of Neuronopathic Gaucher Disease Demonstrates Lysosomal-Autophagic Defects and Altered mTOR Signalling and Is Functionally Rescued by Rapamycin
Glucocerebrosidase (GBA1) mutations are associated with Gaucher disease (GD), an autosomal recessive disorder caused by functional deficiency of glucocerebrosidase (GBA), a lysosomal enzyme that hydrolyzes glucosylceramide to ceramide and glucose. Neuronopathic forms of GD can be associated with rap...
Gespeichert in:
Veröffentlicht in: | The Journal of neuroscience 2016-11, Vol.36 (46), p.11654-11670 |
---|---|
Hauptverfasser: | , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 11670 |
---|---|
container_issue | 46 |
container_start_page | 11654 |
container_title | The Journal of neuroscience |
container_volume | 36 |
creator | Kinghorn, Kerri J Grönke, Sebastian Castillo-Quan, Jorge Iván Woodling, Nathaniel S Li, Li Sirka, Ernestas Gegg, Matthew Mills, Kevin Hardy, John Bjedov, Ivana Partridge, Linda |
description | Glucocerebrosidase (GBA1) mutations are associated with Gaucher disease (GD), an autosomal recessive disorder caused by functional deficiency of glucocerebrosidase (GBA), a lysosomal enzyme that hydrolyzes glucosylceramide to ceramide and glucose. Neuronopathic forms of GD can be associated with rapid neurological decline (Type II) or manifest as a chronic form (Type III) with a wide spectrum of neurological signs. Furthermore, there is now a well-established link between GBA1 mutations and Parkinson's disease (PD), with heterozygote mutations in GBA1 considered the commonest genetic defect in PD. Here we describe a novel Drosophila model of GD that lacks the two fly GBA1 orthologs. This knock-out model recapitulates the main features of GD at the cellular level with severe lysosomal defects and accumulation of glucosylceramide in the fly brain. We also demonstrate a block in autophagy flux in association with reduced lifespan, age-dependent locomotor deficits and accumulation of autophagy substrates in dGBA-deficient fly brains. Furthermore, mechanistic target of rapamycin (mTOR) signaling is downregulated in dGBA knock-out flies, with a concomitant upregulation of Mitf gene expression, the fly ortholog of mammalian TFEB, likely as a compensatory response to the autophagy block. Moreover, the mTOR inhibitor rapamycin is able to partially ameliorate the lifespan, locomotor, and oxidative stress phenotypes. Together, our results demonstrate that this dGBA1-deficient fly model is a useful platform for the further study of the role of lysosomal-autophagic impairment and the potential therapeutic benefits of rapamycin in neuronopathic GD. These results also have important implications for the role of autophagy and mTOR signaling in GBA1-associated PD SIGNIFICANCE STATEMENT: We developed a Drosophila model of neuronopathic GD by knocking-out the fly orthologs of the GBA1 gene, demonstrating abnormal lysosomal pathology in the fly brain. Functioning lysosomes are required for autophagosome-lysosomal fusion in the autophagy pathway. We show in vivo that autophagy is impaired in dGBA-deficient fly brains. In response, mechanistic target of rapamycin (mTOR) activity is downregulated in dGBA-deficient flies and rapamycin ameliorates the lifespan, locomotor, and oxidative stress phenotypes. dGBA knock-out flies also display an upregulation of the Drosophila ortholog of mammalian TFEB, Mitf, a response that is unable to overcome the autophagy block. Together, our resu |
doi_str_mv | 10.1523/JNEUROSCI.4527-15.2016 |
format | Article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5125225</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1841134220</sourcerecordid><originalsourceid>FETCH-LOGICAL-c452t-ef7cc49b1b6df7888c801747f7c2c21ac5c2bdb7dd9865aa0c5216e0db7d8bd23</originalsourceid><addsrcrecordid>eNqNUtFu0zAUtRCIlcEvTH7kJcV24jh9QarabRSVVeq2Z8txblojxw6xM6m_w5fisFHBG36xde45R_f6HoSuKJlTzvJPX--uH_e7-9VmXnAmMsrnjNDyFZql6iJjBaGv0YwwQbKyEMUFehfCd0KIIFS8RRdMVEklihn6ucTrwQffH41V-JtvwGLf4jsYB-98r-LRaHyrRn2EAa9NABUAr6HzLsRBRQh4ewpJ3ymbLceYfNQhKdbQgo4BK9fgpY0wQIO7h90e35uDU9Yad_hd2wR8MzodjZ_QE95D0GPi1umpetWdtHHv0ZtW2QAfXu5L9Hhz_bD6km13t5vVcpvp9AUxg1ZoXSxqWpdNK6qq0lUathAJZppRpblmdVOLpllUJVeKaM5oCWSCqrph-SX6_Ozbj3UHjQaXJrSyH0ynhpP0ysh_K84c5cE_SU4ZZ4wng48vBoP_MUKIsjNBg7XKgR-DpBUnIp08_w9qQWleMEYStXym6rSnMEB77ogSOWVBnrMgpywkTE5ZSMKrv-c5y_4sP_8Fzg-1Zg</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1841134220</pqid></control><display><type>article</type><title>A Drosophila Model of Neuronopathic Gaucher Disease Demonstrates Lysosomal-Autophagic Defects and Altered mTOR Signalling and Is Functionally Rescued by Rapamycin</title><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>Kinghorn, Kerri J ; Grönke, Sebastian ; Castillo-Quan, Jorge Iván ; Woodling, Nathaniel S ; Li, Li ; Sirka, Ernestas ; Gegg, Matthew ; Mills, Kevin ; Hardy, John ; Bjedov, Ivana ; Partridge, Linda</creator><creatorcontrib>Kinghorn, Kerri J ; Grönke, Sebastian ; Castillo-Quan, Jorge Iván ; Woodling, Nathaniel S ; Li, Li ; Sirka, Ernestas ; Gegg, Matthew ; Mills, Kevin ; Hardy, John ; Bjedov, Ivana ; Partridge, Linda</creatorcontrib><description>Glucocerebrosidase (GBA1) mutations are associated with Gaucher disease (GD), an autosomal recessive disorder caused by functional deficiency of glucocerebrosidase (GBA), a lysosomal enzyme that hydrolyzes glucosylceramide to ceramide and glucose. Neuronopathic forms of GD can be associated with rapid neurological decline (Type II) or manifest as a chronic form (Type III) with a wide spectrum of neurological signs. Furthermore, there is now a well-established link between GBA1 mutations and Parkinson's disease (PD), with heterozygote mutations in GBA1 considered the commonest genetic defect in PD. Here we describe a novel Drosophila model of GD that lacks the two fly GBA1 orthologs. This knock-out model recapitulates the main features of GD at the cellular level with severe lysosomal defects and accumulation of glucosylceramide in the fly brain. We also demonstrate a block in autophagy flux in association with reduced lifespan, age-dependent locomotor deficits and accumulation of autophagy substrates in dGBA-deficient fly brains. Furthermore, mechanistic target of rapamycin (mTOR) signaling is downregulated in dGBA knock-out flies, with a concomitant upregulation of Mitf gene expression, the fly ortholog of mammalian TFEB, likely as a compensatory response to the autophagy block. Moreover, the mTOR inhibitor rapamycin is able to partially ameliorate the lifespan, locomotor, and oxidative stress phenotypes. Together, our results demonstrate that this dGBA1-deficient fly model is a useful platform for the further study of the role of lysosomal-autophagic impairment and the potential therapeutic benefits of rapamycin in neuronopathic GD. These results also have important implications for the role of autophagy and mTOR signaling in GBA1-associated PD SIGNIFICANCE STATEMENT: We developed a Drosophila model of neuronopathic GD by knocking-out the fly orthologs of the GBA1 gene, demonstrating abnormal lysosomal pathology in the fly brain. Functioning lysosomes are required for autophagosome-lysosomal fusion in the autophagy pathway. We show in vivo that autophagy is impaired in dGBA-deficient fly brains. In response, mechanistic target of rapamycin (mTOR) activity is downregulated in dGBA-deficient flies and rapamycin ameliorates the lifespan, locomotor, and oxidative stress phenotypes. dGBA knock-out flies also display an upregulation of the Drosophila ortholog of mammalian TFEB, Mitf, a response that is unable to overcome the autophagy block. Together, our results suggest that rapamycin may have potential benefits in the treatment of GD, as well as PD linked to GBA1 mutations.</description><identifier>ISSN: 0270-6474</identifier><identifier>EISSN: 1529-2401</identifier><identifier>DOI: 10.1523/JNEUROSCI.4527-15.2016</identifier><identifier>PMID: 27852774</identifier><language>eng</language><publisher>United States: Society for Neuroscience</publisher><subject>Animals ; Animals, Genetically Modified ; Autophagy - drug effects ; Disease Models, Animal ; Drosophila ; Gaucher Disease - metabolism ; Gaucher Disease - pathology ; Gaucher Disease - prevention & control ; Gene Knockout Techniques ; Glucosylceramidase - genetics ; Lysosomes - metabolism ; Signal Transduction - drug effects ; Sirolimus - administration & dosage ; TOR Serine-Threonine Kinases - metabolism</subject><ispartof>The Journal of neuroscience, 2016-11, Vol.36 (46), p.11654-11670</ispartof><rights>Copyright © 2016 Kinghorn et al.</rights><rights>Copyright © 2016 Kinghorn et al. 2016</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c452t-ef7cc49b1b6df7888c801747f7c2c21ac5c2bdb7dd9865aa0c5216e0db7d8bd23</citedby><cites>FETCH-LOGICAL-c452t-ef7cc49b1b6df7888c801747f7c2c21ac5c2bdb7dd9865aa0c5216e0db7d8bd23</cites><orcidid>0000-0003-2048-4332 ; 0000-0002-1539-5346 ; 0000-0002-0298-3800 ; 0000-0002-6324-2854 ; 0000-0001-8093-0723 ; 0000-0001-8500-5406 ; 0000-0001-9615-0094</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5125225/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5125225/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27852774$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kinghorn, Kerri J</creatorcontrib><creatorcontrib>Grönke, Sebastian</creatorcontrib><creatorcontrib>Castillo-Quan, Jorge Iván</creatorcontrib><creatorcontrib>Woodling, Nathaniel S</creatorcontrib><creatorcontrib>Li, Li</creatorcontrib><creatorcontrib>Sirka, Ernestas</creatorcontrib><creatorcontrib>Gegg, Matthew</creatorcontrib><creatorcontrib>Mills, Kevin</creatorcontrib><creatorcontrib>Hardy, John</creatorcontrib><creatorcontrib>Bjedov, Ivana</creatorcontrib><creatorcontrib>Partridge, Linda</creatorcontrib><title>A Drosophila Model of Neuronopathic Gaucher Disease Demonstrates Lysosomal-Autophagic Defects and Altered mTOR Signalling and Is Functionally Rescued by Rapamycin</title><title>The Journal of neuroscience</title><addtitle>J Neurosci</addtitle><description>Glucocerebrosidase (GBA1) mutations are associated with Gaucher disease (GD), an autosomal recessive disorder caused by functional deficiency of glucocerebrosidase (GBA), a lysosomal enzyme that hydrolyzes glucosylceramide to ceramide and glucose. Neuronopathic forms of GD can be associated with rapid neurological decline (Type II) or manifest as a chronic form (Type III) with a wide spectrum of neurological signs. Furthermore, there is now a well-established link between GBA1 mutations and Parkinson's disease (PD), with heterozygote mutations in GBA1 considered the commonest genetic defect in PD. Here we describe a novel Drosophila model of GD that lacks the two fly GBA1 orthologs. This knock-out model recapitulates the main features of GD at the cellular level with severe lysosomal defects and accumulation of glucosylceramide in the fly brain. We also demonstrate a block in autophagy flux in association with reduced lifespan, age-dependent locomotor deficits and accumulation of autophagy substrates in dGBA-deficient fly brains. Furthermore, mechanistic target of rapamycin (mTOR) signaling is downregulated in dGBA knock-out flies, with a concomitant upregulation of Mitf gene expression, the fly ortholog of mammalian TFEB, likely as a compensatory response to the autophagy block. Moreover, the mTOR inhibitor rapamycin is able to partially ameliorate the lifespan, locomotor, and oxidative stress phenotypes. Together, our results demonstrate that this dGBA1-deficient fly model is a useful platform for the further study of the role of lysosomal-autophagic impairment and the potential therapeutic benefits of rapamycin in neuronopathic GD. These results also have important implications for the role of autophagy and mTOR signaling in GBA1-associated PD SIGNIFICANCE STATEMENT: We developed a Drosophila model of neuronopathic GD by knocking-out the fly orthologs of the GBA1 gene, demonstrating abnormal lysosomal pathology in the fly brain. Functioning lysosomes are required for autophagosome-lysosomal fusion in the autophagy pathway. We show in vivo that autophagy is impaired in dGBA-deficient fly brains. In response, mechanistic target of rapamycin (mTOR) activity is downregulated in dGBA-deficient flies and rapamycin ameliorates the lifespan, locomotor, and oxidative stress phenotypes. dGBA knock-out flies also display an upregulation of the Drosophila ortholog of mammalian TFEB, Mitf, a response that is unable to overcome the autophagy block. Together, our results suggest that rapamycin may have potential benefits in the treatment of GD, as well as PD linked to GBA1 mutations.</description><subject>Animals</subject><subject>Animals, Genetically Modified</subject><subject>Autophagy - drug effects</subject><subject>Disease Models, Animal</subject><subject>Drosophila</subject><subject>Gaucher Disease - metabolism</subject><subject>Gaucher Disease - pathology</subject><subject>Gaucher Disease - prevention & control</subject><subject>Gene Knockout Techniques</subject><subject>Glucosylceramidase - genetics</subject><subject>Lysosomes - metabolism</subject><subject>Signal Transduction - drug effects</subject><subject>Sirolimus - administration & dosage</subject><subject>TOR Serine-Threonine Kinases - metabolism</subject><issn>0270-6474</issn><issn>1529-2401</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNUtFu0zAUtRCIlcEvTH7kJcV24jh9QarabRSVVeq2Z8txblojxw6xM6m_w5fisFHBG36xde45R_f6HoSuKJlTzvJPX--uH_e7-9VmXnAmMsrnjNDyFZql6iJjBaGv0YwwQbKyEMUFehfCd0KIIFS8RRdMVEklihn6ucTrwQffH41V-JtvwGLf4jsYB-98r-LRaHyrRn2EAa9NABUAr6HzLsRBRQh4ewpJ3ymbLceYfNQhKdbQgo4BK9fgpY0wQIO7h90e35uDU9Yad_hd2wR8MzodjZ_QE95D0GPi1umpetWdtHHv0ZtW2QAfXu5L9Hhz_bD6km13t5vVcpvp9AUxg1ZoXSxqWpdNK6qq0lUathAJZppRpblmdVOLpllUJVeKaM5oCWSCqrph-SX6_Ozbj3UHjQaXJrSyH0ynhpP0ysh_K84c5cE_SU4ZZ4wng48vBoP_MUKIsjNBg7XKgR-DpBUnIp08_w9qQWleMEYStXym6rSnMEB77ogSOWVBnrMgpywkTE5ZSMKrv-c5y_4sP_8Fzg-1Zg</recordid><startdate>20161116</startdate><enddate>20161116</enddate><creator>Kinghorn, Kerri J</creator><creator>Grönke, Sebastian</creator><creator>Castillo-Quan, Jorge Iván</creator><creator>Woodling, Nathaniel S</creator><creator>Li, Li</creator><creator>Sirka, Ernestas</creator><creator>Gegg, Matthew</creator><creator>Mills, Kevin</creator><creator>Hardy, John</creator><creator>Bjedov, Ivana</creator><creator>Partridge, Linda</creator><general>Society for Neuroscience</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>7TK</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0003-2048-4332</orcidid><orcidid>https://orcid.org/0000-0002-1539-5346</orcidid><orcidid>https://orcid.org/0000-0002-0298-3800</orcidid><orcidid>https://orcid.org/0000-0002-6324-2854</orcidid><orcidid>https://orcid.org/0000-0001-8093-0723</orcidid><orcidid>https://orcid.org/0000-0001-8500-5406</orcidid><orcidid>https://orcid.org/0000-0001-9615-0094</orcidid></search><sort><creationdate>20161116</creationdate><title>A Drosophila Model of Neuronopathic Gaucher Disease Demonstrates Lysosomal-Autophagic Defects and Altered mTOR Signalling and Is Functionally Rescued by Rapamycin</title><author>Kinghorn, Kerri J ; Grönke, Sebastian ; Castillo-Quan, Jorge Iván ; Woodling, Nathaniel S ; Li, Li ; Sirka, Ernestas ; Gegg, Matthew ; Mills, Kevin ; Hardy, John ; Bjedov, Ivana ; Partridge, Linda</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c452t-ef7cc49b1b6df7888c801747f7c2c21ac5c2bdb7dd9865aa0c5216e0db7d8bd23</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Animals</topic><topic>Animals, Genetically Modified</topic><topic>Autophagy - drug effects</topic><topic>Disease Models, Animal</topic><topic>Drosophila</topic><topic>Gaucher Disease - metabolism</topic><topic>Gaucher Disease - pathology</topic><topic>Gaucher Disease - prevention & control</topic><topic>Gene Knockout Techniques</topic><topic>Glucosylceramidase - genetics</topic><topic>Lysosomes - metabolism</topic><topic>Signal Transduction - drug effects</topic><topic>Sirolimus - administration & dosage</topic><topic>TOR Serine-Threonine Kinases - metabolism</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kinghorn, Kerri J</creatorcontrib><creatorcontrib>Grönke, Sebastian</creatorcontrib><creatorcontrib>Castillo-Quan, Jorge Iván</creatorcontrib><creatorcontrib>Woodling, Nathaniel S</creatorcontrib><creatorcontrib>Li, Li</creatorcontrib><creatorcontrib>Sirka, Ernestas</creatorcontrib><creatorcontrib>Gegg, Matthew</creatorcontrib><creatorcontrib>Mills, Kevin</creatorcontrib><creatorcontrib>Hardy, John</creatorcontrib><creatorcontrib>Bjedov, Ivana</creatorcontrib><creatorcontrib>Partridge, Linda</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>Neurosciences Abstracts</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>The Journal of neuroscience</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kinghorn, Kerri J</au><au>Grönke, Sebastian</au><au>Castillo-Quan, Jorge Iván</au><au>Woodling, Nathaniel S</au><au>Li, Li</au><au>Sirka, Ernestas</au><au>Gegg, Matthew</au><au>Mills, Kevin</au><au>Hardy, John</au><au>Bjedov, Ivana</au><au>Partridge, Linda</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A Drosophila Model of Neuronopathic Gaucher Disease Demonstrates Lysosomal-Autophagic Defects and Altered mTOR Signalling and Is Functionally Rescued by Rapamycin</atitle><jtitle>The Journal of neuroscience</jtitle><addtitle>J Neurosci</addtitle><date>2016-11-16</date><risdate>2016</risdate><volume>36</volume><issue>46</issue><spage>11654</spage><epage>11670</epage><pages>11654-11670</pages><issn>0270-6474</issn><eissn>1529-2401</eissn><abstract>Glucocerebrosidase (GBA1) mutations are associated with Gaucher disease (GD), an autosomal recessive disorder caused by functional deficiency of glucocerebrosidase (GBA), a lysosomal enzyme that hydrolyzes glucosylceramide to ceramide and glucose. Neuronopathic forms of GD can be associated with rapid neurological decline (Type II) or manifest as a chronic form (Type III) with a wide spectrum of neurological signs. Furthermore, there is now a well-established link between GBA1 mutations and Parkinson's disease (PD), with heterozygote mutations in GBA1 considered the commonest genetic defect in PD. Here we describe a novel Drosophila model of GD that lacks the two fly GBA1 orthologs. This knock-out model recapitulates the main features of GD at the cellular level with severe lysosomal defects and accumulation of glucosylceramide in the fly brain. We also demonstrate a block in autophagy flux in association with reduced lifespan, age-dependent locomotor deficits and accumulation of autophagy substrates in dGBA-deficient fly brains. Furthermore, mechanistic target of rapamycin (mTOR) signaling is downregulated in dGBA knock-out flies, with a concomitant upregulation of Mitf gene expression, the fly ortholog of mammalian TFEB, likely as a compensatory response to the autophagy block. Moreover, the mTOR inhibitor rapamycin is able to partially ameliorate the lifespan, locomotor, and oxidative stress phenotypes. Together, our results demonstrate that this dGBA1-deficient fly model is a useful platform for the further study of the role of lysosomal-autophagic impairment and the potential therapeutic benefits of rapamycin in neuronopathic GD. These results also have important implications for the role of autophagy and mTOR signaling in GBA1-associated PD SIGNIFICANCE STATEMENT: We developed a Drosophila model of neuronopathic GD by knocking-out the fly orthologs of the GBA1 gene, demonstrating abnormal lysosomal pathology in the fly brain. Functioning lysosomes are required for autophagosome-lysosomal fusion in the autophagy pathway. We show in vivo that autophagy is impaired in dGBA-deficient fly brains. In response, mechanistic target of rapamycin (mTOR) activity is downregulated in dGBA-deficient flies and rapamycin ameliorates the lifespan, locomotor, and oxidative stress phenotypes. dGBA knock-out flies also display an upregulation of the Drosophila ortholog of mammalian TFEB, Mitf, a response that is unable to overcome the autophagy block. Together, our results suggest that rapamycin may have potential benefits in the treatment of GD, as well as PD linked to GBA1 mutations.</abstract><cop>United States</cop><pub>Society for Neuroscience</pub><pmid>27852774</pmid><doi>10.1523/JNEUROSCI.4527-15.2016</doi><tpages>17</tpages><orcidid>https://orcid.org/0000-0003-2048-4332</orcidid><orcidid>https://orcid.org/0000-0002-1539-5346</orcidid><orcidid>https://orcid.org/0000-0002-0298-3800</orcidid><orcidid>https://orcid.org/0000-0002-6324-2854</orcidid><orcidid>https://orcid.org/0000-0001-8093-0723</orcidid><orcidid>https://orcid.org/0000-0001-8500-5406</orcidid><orcidid>https://orcid.org/0000-0001-9615-0094</orcidid><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0270-6474 |
ispartof | The Journal of neuroscience, 2016-11, Vol.36 (46), p.11654-11670 |
issn | 0270-6474 1529-2401 |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5125225 |
source | MEDLINE; EZB-FREE-00999 freely available EZB journals; PubMed Central |
subjects | Animals Animals, Genetically Modified Autophagy - drug effects Disease Models, Animal Drosophila Gaucher Disease - metabolism Gaucher Disease - pathology Gaucher Disease - prevention & control Gene Knockout Techniques Glucosylceramidase - genetics Lysosomes - metabolism Signal Transduction - drug effects Sirolimus - administration & dosage TOR Serine-Threonine Kinases - metabolism |
title | A Drosophila Model of Neuronopathic Gaucher Disease Demonstrates Lysosomal-Autophagic Defects and Altered mTOR Signalling and Is Functionally Rescued by Rapamycin |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-24T07%3A42%3A59IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%20Drosophila%20Model%20of%20Neuronopathic%20Gaucher%20Disease%20Demonstrates%20Lysosomal-Autophagic%20Defects%20and%20Altered%20mTOR%20Signalling%20and%20Is%20Functionally%20Rescued%20by%20Rapamycin&rft.jtitle=The%20Journal%20of%20neuroscience&rft.au=Kinghorn,%20Kerri%20J&rft.date=2016-11-16&rft.volume=36&rft.issue=46&rft.spage=11654&rft.epage=11670&rft.pages=11654-11670&rft.issn=0270-6474&rft.eissn=1529-2401&rft_id=info:doi/10.1523/JNEUROSCI.4527-15.2016&rft_dat=%3Cproquest_pubme%3E1841134220%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1841134220&rft_id=info:pmid/27852774&rfr_iscdi=true |